-=Lexicon Pharma (LXRX) reported earnings on Thur 22 Feb 2018 (b/o)

Lexicon Pharma beats by $0.14, beats on revs 

• Reports Q4 (Dec) loss of $0.27 per share, $0.14 better than the Capital IQ Consensus of ($0.41); revenues rose 43.7% year/year to $33.05 mln vs the $29.84 mln Capital IQ Consensus.
  • Revs increased, primarily due to milestone payments from the Ipsen alliance for the first commercial sale of XERMELO in the United Kingdom and Germany, and $5.4 million in net product revenues.
• Regulatory Filings for Sotagliflozin in Patients with Type 1 Diabetes Expected in First Quarter of 2018